443 related articles for article (PubMed ID: 24680062)
21. Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
Sheridan GK; Dev KK
Sci Rep; 2014 May; 4():5051. PubMed ID: 24851861
[TBL] [Abstract][Full Text] [Related]
22. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis.
Zhang ZY; Zhang Z; Schluesener HJ
Neuropathol Appl Neurobiol; 2009 Oct; 35(5):487-95. PubMed ID: 19207263
[TBL] [Abstract][Full Text] [Related]
23. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
25. Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720.
Wang F; Tan W; Guo D; He S
Eur J Pharmacol; 2007 Nov; 573(1-3):230-40. PubMed ID: 17716652
[TBL] [Abstract][Full Text] [Related]
26. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
27. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
Payne SG; Oskeritzian CA; Griffiths R; Subramanian P; Barbour SE; Chalfant CE; Milstien S; Spiegel S
Blood; 2007 Feb; 109(3):1077-85. PubMed ID: 17008548
[TBL] [Abstract][Full Text] [Related]
28. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.
Xie JH; Nomura N; Koprak SL; Quackenbush EJ; Forrest MJ; Rosen H
J Immunol; 2003 Apr; 170(7):3662-70. PubMed ID: 12646631
[TBL] [Abstract][Full Text] [Related]
29. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
30. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
31. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
32. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
33. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.
Mizushima T; Ito T; Kishi D; Kai Y; Tamagawa H; Nezu R; Kiyono H; Matsuda H
Inflamm Bowel Dis; 2004 May; 10(3):182-92. PubMed ID: 15290910
[TBL] [Abstract][Full Text] [Related]
35. Fingolimod protects cultured cortical neurons against excitotoxic death.
Di Menna L; Molinaro G; Di Nuzzo L; Riozzi B; Zappulla C; Pozzilli C; Turrini R; Caraci F; Copani A; Battaglia G; Nicoletti F; Bruno V
Pharmacol Res; 2013 Jan; 67(1):1-9. PubMed ID: 23073075
[TBL] [Abstract][Full Text] [Related]
36. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo.
Lan YY; De Creus A; Colvin BL; Abe M; Brinkmann V; Coates PT; Thomson AW
Am J Transplant; 2005 Nov; 5(11):2649-59. PubMed ID: 16212624
[TBL] [Abstract][Full Text] [Related]
37. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
38. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
39. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
40. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720.
Henning G; Ohl L; Junt T; Reiterer P; Brinkmann V; Nakano H; Hohenberger W; Lipp M; Förster R
J Exp Med; 2001 Dec; 194(12):1875-81. PubMed ID: 11748287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
